-

RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of ReShape Lifesciences Inc. (the “Company”) (NasdaqCM: RSLS) and Vyome Therapeutics, Inc. Under the terms of the Proposed Transaction, ReShape shareholders will own approximately 11.1% of the combined company immediately following the closing of the merger, subject to adjustment based on ReShape’s actual net cash at closing compared to a target net cash amount of $5 million. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to ReShape shareholders.

If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-rsls/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
855-768-1857
1100 Poydras St., Suite 960
New Orleans, LA 70163

Industry:

Kahn Swick & Foti, LLC

NASDAQ:RSLS
Release Versions
English

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
855-768-1857
1100 Poydras St., Suite 960
New Orleans, LA 70163

More News From Kahn Swick & Foti, LLC

Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Forte Biosciences, Inc. (NasdaqCM: FBRX) to argenx SE (NasdaqGS: ARGX). Under the terms of the proposed transaction, shareholders of Forte will receive $77.00 in cash for each share of Forte that they own. KSF is seeking to determine whether this consideration and the process that led to it are adeq...

Safety Insurance Group Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Safety Insurance Group Inc. - SAFT

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Safety Insurance Group Inc. (NasdaqGS: SAFT) to an affiliate of Mapfre S.A. Under the terms of the proposed transaction, shareholders of Safety Insurance will receive $105.00 in cash for each share of Safety Insurance that they own. KSF is seeking to determine whether this consideration and the proce...

PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until September 22, 2026 to file lead plaintiff applications in a securities class action lawsuit against PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NasdaqGM: PRCT), if they purchased the Company’s shares between February 28, 2024 and February 25, 2026, inclusive (the “C...
Back to Newsroom